16
Participants
Start Date
July 31, 2009
Primary Completion Date
August 31, 2009
Study Completion Date
August 31, 2009
pMDI budesonide/formotrol 160/4.5 is in group 1
The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
Symbicort 160/4.5 plus Aerochamber Plus included in group 2
Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
Western Sky Medical Research, El Paso
Collaborators (1)
AstraZeneca
INDUSTRY
Western Sky Medical Research
OTHER